Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Licenses IP to EraGen

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies today said that it has signed a settlement and licensing agreement with EraGen Biosciences covering its non-coding patents.

It is the second such licensing deal that Genetic Technologies has signed this week for the intellectual property. On Monday, it had announced that it settled a legal dispute with Gen-Probe over the technology, which resulted in Gen-Probe taking a license.

Gen-Probe was one of several parties named in a suit filed by Genetic Technologies in February. The Australian firm has asserted that the firms named in the suit were infringing a US patent covering methods of analyzing non-coding DNA sequences. Among the firms named in the suit were Gen-Probe, Beckman Coulter, Orchid Cellmark, Interleukin Genetics, Molecular Pathology Laboratory Network, PIC USA, Pioneer Hi-Bred International, and Sunrise Medical Laboratories.

EraGen was not named in the suit, but Genetic Technologies said today that the firms have been engaged in discussions regarding the patents "for some time."

Financial and other terms of the license have not been disclosed by the companies.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.